AGM/EGMMay 15, 2026, 04:29 PM
BioNTech Shareholders Approve All AGM Items, Expands Supervisory Board
AI Summary
BioNTech SE shareholders approved all agenda items at the 2026 Annual General Meeting, with 92% of the share capital represented. Key resolutions included expanding the Supervisory Board from six to eight members and electing Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert to add expertise in clinical development and oncology. Shareholders also extended the mandates of three existing board members and re-elected Helmut Jeggle as Chairman of the Supervisory Board.
Key Highlights
- BioNTech shareholders approved all agenda items at the 2026 Annual General Meeting, with 92% of share capital represented.
- The Supervisory Board was expanded from six to eight members to enhance expertise for the oncology pipeline.
- Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert were elected as new Supervisory Board members.
- Mandates for existing Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, and Prof. Rudolf Staudigl were extended.
- Helmut Jeggle was re-elected as Chairman of the Supervisory Board.
- Shareholders approved the appropriation of the 2025 balance sheet profit with 99.97% of votes.
- The Compensation Report was approved with 96.60% of votes.
- New Authorized Capital 2026 was approved with 99.24% of votes.
Price Impact
More from BNTX